The alleged misuse of two cholesterol-lowering agents has been cautioned against by the French national health insurance agency

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.480, 2005-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cholesterol-Lowering

By  

Current Bioactive Compounds, Vol. 2, Iss. 1, 2006-03 ,pp. : 113-113

Bentham Science Publishers

Access to resources Recommend Favorite

Cholesterol-Lowering

By  

Current Bioactive Compounds, Vol. 2, Iss. 3, 2006-09 ,pp. : 382-383

Bentham Science Publishers

Access to resources Recommend Favorite

Cholesterol-Lowering

By  

Current Bioactive Compounds, Vol. 1, Iss. 1, 2005-04 ,pp. : 72-72

Bentham Science Publishers

Access to resources Recommend Favorite

Cholesterol-Lowering

By  

Current Bioactive Compounds, Vol. 1, Iss. 3, 2005-12 ,pp. : 298-298

Bentham Science Publishers

Access to resources Recommend Favorite

HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent ''direct'' effects on atherosclerotic vessels in high cholesterol diet-fed rabbits

By Mitani H.   Egashira K.   Kimura M.  

Pharmacological Research, Vol. 48, Iss. 5, 2003-11 ,pp. : 417-427

Elsevier

Access to resources Recommend Favorite